Ranbaxy Loses Tamsulosin Launch Opportunity To Impax; Analysts Raise Doubts About Nexium, Lipitor
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - It's been a tricky and awkward situation for Ranbaxy since it admitted at the last minute to losing a big opportunity of launching the first generic version of prostate enlargement drug Flomax (tamsulosin) in the United States. On March 2, Impax launched the generic variant of the nearly $2 billion blockbuster drug as part of an October 2009 patent settlement inked with Boehringer Ingelheim
You may also be interested in...
Ranbaxy-Teva Atorvastatin Mystery Deal Decoded: Many Likely Scenarios Aimed At “On Time” Launch
Industry sources tell PharmAsia News that Ranbaxy forged the Teva Lipitor deal as a back-up plan, one that could prove costly for Ranbaxy.
Ranbaxy-Teva Atorvastatin Mystery Deal Decoded: Many Likely Scenarios Aimed At “On Time” Launch
Industry sources tell PharmAsia News that Ranbaxy forged the Teva Lipitor deal as a back-up plan, one that could prove costly for Ranbaxy.
Will Ranbaxy Tie Up With Teva To Launch Generic Lipitor?
MUMBAI - Breaking a long silence, Ranbaxy Laboratories Ltd. Managing Director Arun Sawhney told investors last week that he is "very optimistic" about keeping the U.S. launch date of generic versions of Lipitor (atorvastatin), the largest pharmaceutical brand